MX2010004813A - Factor viii recombinante que tiene estabilidad incrementada. - Google Patents

Factor viii recombinante que tiene estabilidad incrementada.

Info

Publication number
MX2010004813A
MX2010004813A MX2010004813A MX2010004813A MX2010004813A MX 2010004813 A MX2010004813 A MX 2010004813A MX 2010004813 A MX2010004813 A MX 2010004813A MX 2010004813 A MX2010004813 A MX 2010004813A MX 2010004813 A MX2010004813 A MX 2010004813A
Authority
MX
Mexico
Prior art keywords
factor viii
recombinant factor
increased stability
nucleic acid
acid molecule
Prior art date
Application number
MX2010004813A
Other languages
English (en)
Inventor
Philip J Fay
Hironao Wakabayashi
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Publication of MX2010004813A publication Critical patent/MX2010004813A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

La presente invención se refiere a un factor VIII recombinante que incluye una o más mutaciones que resultan en estabilidad mejorada tanto del factor VIII como factor VIIIa. Los métodos para hacer y usar el factor VIII recombinante, y composiciones farmacéuticas que contienen el mismo también se describen. La presente invención adicionalmente se refiere a una molécula de ácido nucleico aislada que codifica el factor VIII recombinante, así como también sistemas de expresión de ADN y células huésped que contienen la molécula de ácido nucleico aislada.
MX2010004813A 2007-11-01 2008-07-25 Factor viii recombinante que tiene estabilidad incrementada. MX2010004813A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98451807P 2007-11-01 2007-11-01
US99130407P 2007-11-30 2007-11-30
PCT/US2008/071170 WO2009058446A1 (en) 2007-11-01 2008-07-25 Recombinant factor viii having increased stability

Publications (1)

Publication Number Publication Date
MX2010004813A true MX2010004813A (es) 2010-10-04

Family

ID=40588749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004813A MX2010004813A (es) 2007-11-01 2008-07-25 Factor viii recombinante que tiene estabilidad incrementada.

Country Status (13)

Country Link
US (4) US8338571B2 (es)
EP (2) EP2209908B1 (es)
JP (2) JP2011502478A (es)
KR (1) KR20100113478A (es)
CN (2) CN101965409A (es)
AU (1) AU2008319183B2 (es)
BR (1) BRPI0818913A2 (es)
CA (1) CA2703948A1 (es)
IL (1) IL205422A0 (es)
MX (1) MX2010004813A (es)
RU (2) RU2531493C2 (es)
WO (1) WO2009058446A1 (es)
ZA (1) ZA201003049B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028900A1 (en) * 2006-06-30 2012-02-02 Kaufman Randal J Method of producing factor viii proteins by recombinant methods
US20080070251A1 (en) * 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US9234192B2 (en) 2010-02-16 2016-01-12 Novo Nordisk A/S Conjugated proteins
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8637448B2 (en) * 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
DE102010042458A1 (de) * 2010-10-14 2012-04-19 Siemens Aktiengesellschaft Verfahren zum Betreiben einer kombinierten Gas- und Dampfturbinenanlage sowie zur Durchführung des Verfahrens hergerichtete Gas- und Dampfturbinenanlage und entsprechende Regelvorrichtung
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
RS59833B1 (sr) 2012-02-15 2020-02-28 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
WO2014011819A2 (en) 2012-07-11 2014-01-16 Amunix Operating Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
CA2906602A1 (en) 2013-03-15 2014-09-25 Bayer Healthcare Llc Variant factor viii polypeptides and methods of their production and use
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP4108254A1 (en) * 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3060242A1 (en) * 2013-10-22 2016-08-31 DBV Technologies Method of treating haemophilia by inducing tolerance to blood factors
CN103613658B (zh) * 2013-11-15 2015-04-01 同路生物制药股份有限公司 一种人第viii凝血因子的制备方法
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
WO2017053677A1 (en) * 2015-09-24 2017-03-30 Biomarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
JP2022512787A (ja) * 2018-10-23 2022-02-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子機能を調節するための組成物および方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5880327A (en) 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US5994310A (en) * 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
ES2252028T3 (es) * 1999-07-13 2006-05-16 Biovitrum Ab Composiciones estables del factor viii.
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
CN1205221C (zh) 2000-09-19 2005-06-08 埃默里大学 修饰的凝血因子ⅷ
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
ES2331909T3 (es) * 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
WO2005055930A2 (en) * 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
MXPA06014095A (es) * 2004-06-04 2007-08-07 Camurus Ab Formulaciones de deposito de lipidos.

Also Published As

Publication number Publication date
CN101965409A (zh) 2011-02-02
BRPI0818913A2 (pt) 2015-05-12
US9072722B2 (en) 2015-07-07
KR20100113478A (ko) 2010-10-21
US20090118185A1 (en) 2009-05-07
EP2711436A1 (en) 2014-03-26
US20090118184A1 (en) 2009-05-07
US20140056861A1 (en) 2014-02-27
ZA201003049B (en) 2012-11-28
AU2008319183B2 (en) 2014-09-04
US20130085110A1 (en) 2013-04-04
IL205422A0 (en) 2010-12-30
CA2703948A1 (en) 2009-05-07
RU2014129759A (ru) 2016-02-10
US8183345B2 (en) 2012-05-22
EP2209908A4 (en) 2011-06-01
EP2209908B1 (en) 2014-09-03
JP2015110589A (ja) 2015-06-18
CN104152489A (zh) 2014-11-19
RU2531493C2 (ru) 2014-10-20
US8338571B2 (en) 2012-12-25
RU2010122052A (ru) 2011-12-10
EP2209908A1 (en) 2010-07-28
JP2011502478A (ja) 2011-01-27
WO2009058446A1 (en) 2009-05-07
AU2008319183A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
MX2010004813A (es) Factor viii recombinante que tiene estabilidad incrementada.
MX2009002816A (es) Proteinas de fusion de albumina.
CY1117401T1 (el) Πρωτεϊνες συντηξης αλβουμινης
TNSN08064A1 (en) Albumin fusion proteins
DK1928901T3 (da) Polypeptider, der har beta-glucosidaseaktivitet og polynukleotider, der koder for samme
ATE483027T1 (de) Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
IN2012DN00403A (es)
MY177065A (en) 4-1bb binding molecules
MX2007007862A (es) Proteasas fungales acidas.
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
CY1114483T1 (el) Νεα ρυθμιστικα στοιχεια
MX2010001490A (es) Acidos nucleicos de enlace sdf-1 y uso de los mismos.
WO2007136835A3 (en) Methods and cells for creating functional diversity and uses thereof
CL2008003596A1 (es) Fitasa enzimaticamente susceptible, polinucleotido que la codifica, casete de expresion, vector y celula huesped que comprenden dicho acido nucleico; metodo de preparacion de la fitasa, y composiciones que la comprenden.
WO2010147462A9 (en) Novel stringent selectable markers
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
NZ583783A (en) Avian interferon-lambda polypeptide and genetic sequences encoding the same
WO2013013017A3 (en) Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
IN2015DN03206A (es)
WO2009010251A8 (en) Mutant dna polymerases and related methods
CY1110024T1 (el) Πολυπεπτιδια που εχουν αντιμικροβιακη δραστικοτητα και πολυνουκλεοτιδια που τα κωδικοποιουν
WO2009111336A3 (en) Methods of purifying plasmid dna
ATE514718T1 (de) Peptabody für krebsbehandlung

Legal Events

Date Code Title Description
FG Grant or registration